accountin 2010. The increase in revenues was primarily due to additional revenue recognized under our collaboration agreements with Eli Lilly and Company (Lilly) and Medicis and increased revenues from our neglected diseases initiatives. Research and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Anacor Pharmaceuticals Reports First Quarter 2011 Financial Results
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account